common.study.topics.clinical

Therapy Duration Study in Metastatic Melanoma

common.study.values.description

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously. Researchers want to see if the two ways of giving this type of treatment work equally well in extending the life of patients with melanoma, or not.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Intermittent PD-1 inhibitor therapy

Drug - Continuous PD-1 inhibitor therapy

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

common.study.values.clinical-trial-id

NCT02821013

participant.views.study.view.id

RdGAKa